Fluidigm has a fifty-two week low of $2.67 and a fifty-two week high of $7.51. The company has a current ratio of 1.45, a quick ratio of 1.03 and a debt-to-equity ratio of 0.68. The firm has a market capitalization of $283.76 million, a P/E ratio of -4.76 and a beta of 1.14. The firm’s 50-day moving average is $3.65 and its 200-day moving average is $4.07.
Fluidigm (NASDAQ:FLDM – Get Rating) last issued its quarterly earnings results on Thursday, February 17th. The medical research company reported ($0.06) earnings per share for the quarter. Fluidigm had a negative return on equity of 40.15% and a negative net margin of 45.36%. The business had revenue of $38.27 million during the quarter.
A number of institutional investors have recently made changes to their positions in FLDM. Barclays PLC boosted its stake in shares of Fluidigm by 197.0% in the 4th quarter. Barclays PLC now owns 92,477 shares of the medical research company’s stock valued at $362,000 after buying an additional 61,341 shares during the period. Metropolitan Life Insurance Co NY raised its stake in shares of Fluidigm by 22.7% during the fourth quarter. Metropolitan Life Insurance Co NY now owns 21,112 shares of the medical research company’s stock worth $83,000 after purchasing an additional 3,910 shares during the last quarter. Cubist Systematic Strategies LLC purchased a new stake in shares of Fluidigm during the fourth quarter worth approximately $70,000. D. E. Shaw & Co. Inc. raised its position in Fluidigm by 13.0% in the fourth quarter. D. E. Shaw & Co. Inc. now owns 891,635 shares of the medical research company’s stock worth $3,496,000 after acquiring an additional 102,428 shares in the last quarter. Finally, PDT Partners LLC grew its holdings in Fluidigm by 16.6% in the fourth quarter. PDT Partners LLC now owns 149,136 shares of the medical research company’s stock valued at $585,000 after purchasing an additional 21,236 shares during the last quarter. Institutional investors own 76.59% of the company’s stock.
Fluidigm Company Profile (Get Rating)
Fluidigm Corporation creates, manufactures, and markets instruments, consumables, reagents, and software for researchers and clinical laboratories worldwide. It offers analytical systems, such as Helios, a CyTOF system, as well as Hyperion imaging systems, Hyperion tissue imagers, and flow conductors; and assays and reagents, including Maxpar reagents, Maxpar direct immune profiling assays, Maxpar on demand reagents, and IMC panel kits for immuno-oncology.
- Get a free copy of the StockNews.com research report on Fluidigm (FLDM)
- Why is Chevron Stock Falling After Strong Earnings?
- MarketBeat: Week in Review 4/25 – 4/29
- Apple’s Numbers Complete Trifecta
- Rogers Communication Stock Should Be Launching Higher
- Iridium Communications Stock is Ready to Return to Orbit
Receive News & Ratings for Fluidigm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fluidigm and related companies with MarketBeat.com's FREE daily email newsletter.